Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 2/20 | 0.55 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RARG | P13631 | 2/20 | 0.46 |
| ▸ | RXRA | P19793 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13430422 | 0.87 | GRN (0.49) | GRNSORT1PTGS1CDK8MAPK14 | |
| SCHEMBL4053403 | 0.85 | PTGS2 (0.60) | PTGS1NPC1TP53MAPTRAB9A | |
| SCHEMBL29397174 | 0.85 | RARG (0.47) | GRNSORT1PTGS1CDK8NPC1 | |
| SCHEMBL2082052 | 0.85 | GRN (0.55) | GRNSORT1TP53MAPTMAPK14 | |
| SCHEMBL10234076 | 0.85 | CDK8 (0.46) | GRNSORT1PTGS1CDK8NPC1 | |
| SCHEMBL1409505 | 0.85 | PTGS1 (0.57) | GRNSORT1PTGS1CDK8MAPK14 | |
| SCHEMBL5093845 | 0.82 | MAPK14 (0.53) | GRNSORT1CDK8MAPK14MAPK13 | |
| SCHEMBL1283896 | 0.81 | CDK8 (0.47) | GRNSORT1CDK8NPC1TP53 | |
| SCHEMBL2081991 | 0.81 | ALDH1A1 (0.54) | PTGS1CDK8MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1264553 | 0.81 | CYP1A2 (0.61) | GRNSORT1PTGS1NPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119060018-A | N, N-diaryl urea derivative and application thereof | 杭州百新生物医药科技有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20230089368-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | ANAGENESIS BIOTECHNOLOGIES S.A.S. (FR) | 2023-03-23 | — | — | US | disclosed |
| EP-3999057-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | ANAGENESIS BIOTECHNOLOGIES SAS (FR) | 2022-05-25 | — | — | EP | disclosed |
| CN-114144410-A | Polyarylurea derivatives and their use in the treatment of muscular diseases | 阿纳格纳斯生物技术股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| WO-2021013712-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | ANAGENESIS BIOTECHNOLOGIES S.A.S. (FR) | 2021-01-28 | — | — | WO | disclosed |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| EP-2509595-B1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LTD (GB) | 2018-04-11 | — | — | EP | disclosed |
| EP-2509595-B1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LTD (GB) | 2018-04-11 | — | — | EP | disclosed |
| US-20180000830-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P-59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| US-20180000830-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P-59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| EP-1874770-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | Novartis Pharma AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| CN-101103023-A | Disubstituted ureas as kinase inhibitors | NOVARTIS AG (CH) | 2008-01-09 | — | — | CN | disclosed |
| CN-101010315-A | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER PHARMACEUTICALS CORP (US) | 2007-08-01 | — | — | CN | disclosed |
| WO-2007064872-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064872-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007059202-A2 | PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE AG (DE) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007059202-A2 | PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE AG (DE) | 2007-05-24 | — | — | WO | disclosed |
| EP-1751139-A2 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Bayer Pharmaceuticals Corporation (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2006108640-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| WO-2005110994-A2 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000830-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P-59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | HCK, CDK9, PHKG1 | GRN 3752/4885SORT1 3649/4885PTGS1 2097/4885 |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | MAPK1, MAP3K1, MAPK3 | GRN 2709/4885SORT1 4701/4885PTGS1 315/4885 |
| US-20230089368-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | CKMT1A; CKMT1B, TNNC1, UBQLN2 | GRN 773/4885SORT1 4524/4885PTGS1 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.